Several CYP2B6 genotypes were associated with the metabolism of CYP2B6 substrate drugs, including cyclophosphamide and tamoxifen, frequently used in adjuvant therapy for breast cancer [22]. This evidence concerns the gene CYP2B6 and breast carcinoma.